Evidence map›Paper›PMID 42004350›Full record

ArticleACS omega2026

Piperazine-Thiourea Hybrids as Novel Antiplatelet Agents Targeting COX-1: Synthesis,

Gabriel Rodrigues Coutinho Pereira, Gil Mendes Viana, Mariana Borges Huber, Pryscila Santiago Rodrigues, Anna Rita Santiago de Paula Gonçalves, Plínio Cunha Sathler, Carlos Rangel Rodrigues, Bárbara de Azevedo Abrahim-Vieira, Lucio Mendes Cabral

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Gabriel Rodrigues Coutinho Pereira†Laboratory of Molecular Modeling and QSAR; ‡Laboratory of Industrial Pharmaceutical Technology; §Laboratory of Experimental Hemostasis; Federal University of Rio de Janeiro, Carlos Chagas Filho Avenue, 373, Rio de Janeiro, 21941-902, Brazil.
Gil Mendes Viana†Laboratory of Molecular Modeling and QSAR; ‡Laboratory of Industrial Pharmaceutical Technology; §Laboratory of Experimental Hemostasis; Federal University of Rio de Janeiro, Carlos Chagas Filho Avenue, 373, Rio de Janeiro, 21941-902, Brazil.
Mariana Borges Huber†Laboratory of Molecular Modeling and QSAR; ‡Laboratory of Industrial Pharmaceutical Technology; §Laboratory of Experimental Hemostasis; Federal University of Rio de Janeiro, Carlos Chagas Filho Avenue, 373, Rio de Janeiro, 21941-902, Brazil.
Pryscila Santiago Rodrigues†Laboratory of Molecular Modeling and QSAR; ‡Laboratory of Industrial Pharmaceutical Technology; §Laboratory of Experimental Hemostasis; Federal University of Rio de Janeiro, Carlos Chagas Filho Avenue, 373, Rio de Janeiro, 21941-902, Brazil.
Anna Rita Santiago de Paula Gonçalves†Laboratory of Molecular Modeling and QSAR; ‡Laboratory of Industrial Pharmaceutical Technology; §Laboratory of Experimental Hemostasis; Federal University of Rio de Janeiro, Carlos Chagas Filho Avenue, 373, Rio de Janeiro, 21941-902, Brazil.
Plínio Cunha Sathler†Laboratory of Molecular Modeling and QSAR; ‡Laboratory of Industrial Pharmaceutical Technology; §Laboratory of Experimental Hemostasis; Federal University of Rio de Janeiro, Carlos Chagas Filho Avenue, 373, Rio de Janeiro, 21941-902, Brazil.ORCID https://orcid.org/0000-0003-1203-3179
Carlos Rangel Rodrigues†Laboratory of Molecular Modeling and QSAR; ‡Laboratory of Industrial Pharmaceutical Technology; §Laboratory of Experimental Hemostasis; Federal University of Rio de Janeiro, Carlos Chagas Filho Avenue, 373, Rio de Janeiro, 21941-902, Brazil.
Bárbara de Azevedo Abrahim-Vieira†Laboratory of Molecular Modeling and QSAR; ‡Laboratory of Industrial Pharmaceutical Technology; §Laboratory of Experimental Hemostasis; Federal University of Rio de Janeiro, Carlos Chagas Filho Avenue, 373, Rio de Janeiro, 21941-902, Brazil.
Lucio Mendes Cabral†Laboratory of Molecular Modeling and QSAR; ‡Laboratory of Industrial Pharmaceutical Technology; §Laboratory of Experimental Hemostasis; Federal University of Rio de Janeiro, Carlos Chagas Filho Avenue, 373, Rio de Janeiro, 21941-902, Brazil.ORCID https://orcid.org/0000-0002-4550-5729

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiovascular diseases (CVDs) remain the leading cause of mortality worldwide, reinforcing the need for safer and more effective antiplatelet therapies. In this work, we designed and synthesized a series of piperazine-derived thioureas under mild conditions and evaluated their antiplatelet potential through

Identifiers

PMID42004350
PMCPMC13084458

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.